Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis

Kurt G. Naber*, Yong Hyun Cho, Tetsuro Matsumoto, Anthony J Schaeffer

*Corresponding author for this work

Research output: Contribution to journalShort survey

81 Citations (Scopus)

Abstract

Recurrent urinary tract infections (UTIs) are very common, particularly among women in their reproductive years. Alternatives to antibacterial prophylaxis are needed, particularly measures to increase host defences. Various bacterial lysates have been proposed with this indication. The objective of this review and meta-analysis was to assess the efficacy and safety of bacterial lysates in the management of recurrent UTIs. Electronic databases identified 11 studies with the descriptors 'urinary tract infection', 'immunotherapy' or 'vaccines' and 'double blind'. Seven of the studies dealt with an oral immunostimulant (OM-89), of which about five (1000 adult patients) were retained for analysis with an observation period of 6-12 months. The mean number of UTIs was significantly lower in OM-89-treated patients in all the trials analysed (mean 39%), as was the use of antibacterials. Four of the studies dealt with a vaginal vaccine, of which three small studies were retained for analysis (220 adult patients). The results suggest that this vaginal vaccine is effective when administered with a booster cycle (no recurrent UTI in 50% vs. 14% with placebo). No blind controlled studies could be identified with other bacterial lysates claiming the same indication. In conclusion, among the various immunotherapeutic products, studies were published only for one product (OM-89) that are in accordance with current standards. This product was shown to be effective under conditions of daily practice. The second product (vaginal vaccine) also appears to be effective but adequate phase III studies are necessary.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalInternational Journal of Antimicrobial Agents
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Urinary Tract Infections
Meta-Analysis
Vaccines
Immunologic Adjuvants
Immunotherapy
Placebos
Observation
Databases
Safety
OM 89
Broncho-Vaxom

Keywords

  • Bacterial lysates
  • Clinical review
  • Meta-analysis
  • OM-89
  • SolcoUrovac
  • Urinary tract infections
  • Uro-Vaxom

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Naber, Kurt G. ; Cho, Yong Hyun ; Matsumoto, Tetsuro ; Schaeffer, Anthony J. / Immunoactive prophylaxis of recurrent urinary tract infections : a meta-analysis. In: International Journal of Antimicrobial Agents. 2009 ; Vol. 33, No. 2. pp. 111-119.
@article{84df180d79404e649524dfcf44b0aa88,
title = "Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis",
abstract = "Recurrent urinary tract infections (UTIs) are very common, particularly among women in their reproductive years. Alternatives to antibacterial prophylaxis are needed, particularly measures to increase host defences. Various bacterial lysates have been proposed with this indication. The objective of this review and meta-analysis was to assess the efficacy and safety of bacterial lysates in the management of recurrent UTIs. Electronic databases identified 11 studies with the descriptors 'urinary tract infection', 'immunotherapy' or 'vaccines' and 'double blind'. Seven of the studies dealt with an oral immunostimulant (OM-89), of which about five (1000 adult patients) were retained for analysis with an observation period of 6-12 months. The mean number of UTIs was significantly lower in OM-89-treated patients in all the trials analysed (mean 39{\%}), as was the use of antibacterials. Four of the studies dealt with a vaginal vaccine, of which three small studies were retained for analysis (220 adult patients). The results suggest that this vaginal vaccine is effective when administered with a booster cycle (no recurrent UTI in 50{\%} vs. 14{\%} with placebo). No blind controlled studies could be identified with other bacterial lysates claiming the same indication. In conclusion, among the various immunotherapeutic products, studies were published only for one product (OM-89) that are in accordance with current standards. This product was shown to be effective under conditions of daily practice. The second product (vaginal vaccine) also appears to be effective but adequate phase III studies are necessary.",
keywords = "Bacterial lysates, Clinical review, Meta-analysis, OM-89, SolcoUrovac, Urinary tract infections, Uro-Vaxom",
author = "Naber, {Kurt G.} and Cho, {Yong Hyun} and Tetsuro Matsumoto and Schaeffer, {Anthony J}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.ijantimicag.2008.08.011",
language = "English (US)",
volume = "33",
pages = "111--119",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

Immunoactive prophylaxis of recurrent urinary tract infections : a meta-analysis. / Naber, Kurt G.; Cho, Yong Hyun; Matsumoto, Tetsuro; Schaeffer, Anthony J.

In: International Journal of Antimicrobial Agents, Vol. 33, No. 2, 01.02.2009, p. 111-119.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Immunoactive prophylaxis of recurrent urinary tract infections

T2 - a meta-analysis

AU - Naber, Kurt G.

AU - Cho, Yong Hyun

AU - Matsumoto, Tetsuro

AU - Schaeffer, Anthony J

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Recurrent urinary tract infections (UTIs) are very common, particularly among women in their reproductive years. Alternatives to antibacterial prophylaxis are needed, particularly measures to increase host defences. Various bacterial lysates have been proposed with this indication. The objective of this review and meta-analysis was to assess the efficacy and safety of bacterial lysates in the management of recurrent UTIs. Electronic databases identified 11 studies with the descriptors 'urinary tract infection', 'immunotherapy' or 'vaccines' and 'double blind'. Seven of the studies dealt with an oral immunostimulant (OM-89), of which about five (1000 adult patients) were retained for analysis with an observation period of 6-12 months. The mean number of UTIs was significantly lower in OM-89-treated patients in all the trials analysed (mean 39%), as was the use of antibacterials. Four of the studies dealt with a vaginal vaccine, of which three small studies were retained for analysis (220 adult patients). The results suggest that this vaginal vaccine is effective when administered with a booster cycle (no recurrent UTI in 50% vs. 14% with placebo). No blind controlled studies could be identified with other bacterial lysates claiming the same indication. In conclusion, among the various immunotherapeutic products, studies were published only for one product (OM-89) that are in accordance with current standards. This product was shown to be effective under conditions of daily practice. The second product (vaginal vaccine) also appears to be effective but adequate phase III studies are necessary.

AB - Recurrent urinary tract infections (UTIs) are very common, particularly among women in their reproductive years. Alternatives to antibacterial prophylaxis are needed, particularly measures to increase host defences. Various bacterial lysates have been proposed with this indication. The objective of this review and meta-analysis was to assess the efficacy and safety of bacterial lysates in the management of recurrent UTIs. Electronic databases identified 11 studies with the descriptors 'urinary tract infection', 'immunotherapy' or 'vaccines' and 'double blind'. Seven of the studies dealt with an oral immunostimulant (OM-89), of which about five (1000 adult patients) were retained for analysis with an observation period of 6-12 months. The mean number of UTIs was significantly lower in OM-89-treated patients in all the trials analysed (mean 39%), as was the use of antibacterials. Four of the studies dealt with a vaginal vaccine, of which three small studies were retained for analysis (220 adult patients). The results suggest that this vaginal vaccine is effective when administered with a booster cycle (no recurrent UTI in 50% vs. 14% with placebo). No blind controlled studies could be identified with other bacterial lysates claiming the same indication. In conclusion, among the various immunotherapeutic products, studies were published only for one product (OM-89) that are in accordance with current standards. This product was shown to be effective under conditions of daily practice. The second product (vaginal vaccine) also appears to be effective but adequate phase III studies are necessary.

KW - Bacterial lysates

KW - Clinical review

KW - Meta-analysis

KW - OM-89

KW - SolcoUrovac

KW - Urinary tract infections

KW - Uro-Vaxom

UR - http://www.scopus.com/inward/record.url?scp=58149264765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149264765&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2008.08.011

DO - 10.1016/j.ijantimicag.2008.08.011

M3 - Short survey

C2 - 18963856

AN - SCOPUS:58149264765

VL - 33

SP - 111

EP - 119

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -